Axoltis Pharma to attend BIO International Convention 2026 in San Diego

Axoltis Pharma announces its participation in the BIO International Convention, taking place from June 22 to 25, 2026, at the San Diego Convention Center in San Diego, CA, United-States.

The BIO International Convention is one of the world’s premier biotechnology partnering events, bringing together biotechnology companies, pharmaceutical leaders, investors, research institutions and innovation stakeholders from across the life sciences ecosystem. 

Yann Godfrin, Chief Executive Officer of Axoltis Pharma, and Luca Bolliger, Chief Business Officer, will represent the company on site and will be available to engage in partnering discussions throughout the event.

Axoltis Pharma  is currently conducting SEALS, a Phase 2 clinical trial evaluating the effects of NX210c in patients with Amyotrophic Lateral Sclerosis (ALS).

Axoltis Pharma will be part of the French delegation, alongside more than 100 companies, with the support of Business France Healthcare North America.

Meet us in San Diego

Axoltis Pharma looks forward to meeting partners and stakeholders in San Diego to explore collaboration opportunities and advance discussions around its clinical programs.